How many times have you read that transgender individuals need surgery to keep them from slipping into bad mental health or even from committing suicide?
“For many trans folks, existing daily in a body that doesn’t match your sense of self isn’t just uncomfortable, it’s traumatic,” Laura A. Jacobs, an LGBT counsellor in New York told NBC earlier this year.
And that’s why transgender advocates are lobbying for quick resumption of sex reassignment surgery during the COVID-19 pandemic. Otherwise, these people could suffer great harm.
“There’s a lot of research that shows that delaying treatment for trans people increases levels of depression, anxiety and suicidal ideation,” says Ms. Jacobs.
One of the most-highly praised of these studies was an article published in October in the American Journal of Psychiatry (paywall). It found that transgender individuals who underwent gender-affirming surgery were significantly less likely to seek mental health treatment for depression and anxiety disorders or attempt suicide afterwards.
“This first total population study of #transgender individuals diagnosed with gender dysphoria lends support to the decision to provide gender-affirming surgeries to those who seek them,” the journal tweeted.
But, ooops, it didn’t.
This week the journal published a correction (paywall) – a very significant one. After protests, letters to the editor and closer scrutiny of the statistical methods, it appears that “the results demonstrated no advantage of surgery in relation to subsequent mood or anxiety disorder-related health care visits or prescriptions or hospitalizations following suicide attempts in that comparison”.
Furthermore, the authors’ “conclusion that ‘the longitudinal association between gender-affirming surgery and lower use of mental health treatment lends support to the decision to provide gender-affirming surgeries to transgender individuals who seek them’ is too strong”.
There is no question that transgender individuals have mental health difficulties. The journal article was praised even by critics like Mark Regnerus for revealing the scale of the problem. Based on a study of 9.5 million Swedes between 2005 and 2015, it found that: “individuals with a gender incongruence diagnosis were about six times as likely to have had a mood and anxiety disorder health care visit, more than three times as likely to have received prescriptions for antidepressants and anxiolytics, and more than six times as likely to have been hospitalized after a suicide attempt”.
Naturally, the transgender lobby claims that these troubling statistics are due to widespread stigma; skeptics counter that gender dysphoria is a mental health issue.
But the question is what to do about it.
The solutions proposed by transgender activists are first social affirmation, then cross-sex hormones, and finally, amputations – usually mastectomies for women and removal of genitalia for men. Surgery, they tell people suffering from gender dysphoria, will give you peace.
But this, it turns out, is not true. The researchers jumped the gun.
As the Society for Evidence-Based Gender Medicine commented about this debacle, “Sometimes in our eagerness to reach a goal, we opt for the appealing short-cut, but it takes more time in the end. Gender dysphoric people deserve high-quality healthcare. It requires rigorously-designed studies, research that follows the evidence, however hard the path.”
The reality is that there is no rigorous evidence for treating boys and girls and men and women who suffer from gender dysphoria with hormones and surgery. It is basically experimental medicine, a 21st century version of the disasters of thalidomide and frontal lobotomies.
This article has been republished from MercatorNet under a Creative Commons license.
Big Tech is suppressing our reach, refusing to let us advertise and squelching our ability to serve up a steady diet of truth and ideas. Help us fight back by becoming a member for just $5 a month and then join the discussion on Parler @CharlemagneInstitute and Gab @CharlemagneInstitute!
Michael Cook likes bad puns, bushwalking and black coffee. He did a B.A. at Harvard University in the U.S. where it was good for networking, but moved to Sydney where it wasn’t. He also did a Ph.D. on an obscure corner of Australian literature. Currently he is the editor of BioEdge, a newsletter about bioethics, and MercatorNet. He also writes a bioethics column for Australasian Science.